Результаты поиска

Прогнозируемое значение изолированной Беты 2-Microglobulin Возвращение в тайскую Множественную миелому: влияние оценки реалов.

ИСТОРИЯ ВОПРОСА: 2024 Международная рабочая группа < < Миэлома > > (Миломское общество)2- микроглобулин (β2M) с нормальной сывороткой креатинин (SCr) в виде множественной миэломы высокого риска (MM). Однако определения почек на основе креатинина могут быть неточными для азиатских популяций с меньшей массой мышц. Мы стремились оценить прогнозируемое воздействие изолированного повышенного уровня β2M на общее выживание (ОС) с использованием определений, основанных на Креатинине Кр и Коккрофт-Го (CrCl). МЕТОДЫ: Это ретроспективное исследование охватывало новых пациентов с диагнозом MM

Совпадение в аннотации оригинала
BACKGROUND: The 2024 International Myeloma Society-International Myeloma Working Group consensus classifies isolated elevated β2-microglobulin (β2M) with normal serum creatinine (SCr) as high-risk multiple myeloma (MM). However, creatinine-based renal definitions may be inaccurate in Asian populations with lower muscle mass. We aimed to evaluate the prognost…

Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.

Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). While life-threatening toxicities like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are well-characterized, musculoskeletal adverse events (MSK AEs) remain poorly understood despite their potential to significantly impact quality of life. To characterize the incidence, clinical features, temporal patterns, and immunological correlates of MSK AEs following commercial BCMA CAR-T therapy in…

Correction: Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience.

[This corrects the article DOI: 10.3389/fonc.2026.1765235.].

Choroidal Leakage during Daratumumab Therapy: A Desensitization-Based Strategy for Treatment Continuation in Relapsed/Refractory Multiple Myeloma.

BACKGROUND: Daratumumab is widely used in relapsed/refractory multiple myeloma, but ocular adverse events are rare and not well-characterized. CASE PRESENTATION: A 68-year-old woman developed acute blurred vision during the second day of her first daratumumab infusion. Multimodal imaging, including fluorescein angiography, indocyanine green angiography, and optical coherence tomography (OCT), demonstrated bilateral choroidal leakage with subretinal fluid and choroidal vascular changes. MANAGEMENT AND OUTCOME: Daratumumab was temporarily discontinued due to suspected drug-related ocular toxic…

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Minimal residual disease (MRD) status is widely used to assess depth of response and predict outcome in multiple myeloma, but bone marrow MRD testing is invasive and subject to sampling variability. Blood-based mass spectrometry (MS), which measures patient-specific monoclonal immunoglobulins, offers a non-invasive approach to monitoring residual disease. Using the structured assessment schedule of the CASSIOPEIA trial, we compared serum MS with bone marrow MRD by next-generation flow cytometry (NGF) and next-generation sequencing (NGS). This retrospective post-hoc analysis included 237 patien…

Persistence to Multiple Myeloma Treatments Given at First Relapse-Results From the Australian Real-World OPTIMISE Study.

BACKGROUND: Daratumumab became publicly available in Australia in 2021 in combination with bortezomib and dexamethasone (DVd), as a second-line (2L) therapy for multiple myeloma (MM). We evaluated real-world persistence to any MM treatment after first relapse before and after DVd availability using the Pharmaceutical Benefits Scheme 10% sample dataset. METHODS: Dispensing records for adults receiving 2L MM treatment from January 2018 to December 2020 (Period 1) and January 2021 to April 2025 (Period 2) were analyzed using Kaplan-Meier to determine treatment persistence. RESULTS: Eighty patie…

When Prostate Cancer Mimics Multiple Myeloma: Diffuse Bone Marrow Infiltration Revealing Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation.

Diffuse bone marrow infiltration is an uncommon manifestation of metastatic prostate adenocarcinoma and may mimic hematologic malignancies such as multiple myeloma, resulting in diagnostic delay. Neuroendocrine differentiation further complicates the clinical presentation because of its aggressive biological behavior and atypical metastatic pattern. We report a rare case of metastatic prostate adenocarcinoma with neuroendocrine differentiation revealed by diffuse bone marrow infiltration. A 59-year-old man presented with diffuse bone pain and pancytopenia and was initially admitted to the hema…

A solitary lytic rib lesion mimicking primary Chest Wall malignancy as the initial presentation of multiple myeloma.

Multiple myeloma is predominantly observed in the geriatric population and accounts for approximately 10% of all hematologic malignancies. It typically presents with multiple bone lesions and clinical features fulfilling the CRAB criteria (hyperCalcemia, Renal failure, Anemia, and Bone involvement). Herein, we present the case of an 82-year-old patient who presented with a solitary lytic rib lesion in the left hemithorax. The patient exhibited only bone pain among the CRAB features, and systemic radiological evaluation revealed no additional lesions. The initial clinical impression was that of…

Hemophagocytic Lymphohistiocytosis as a Clinical Harbinger of Rapid Disease Progression in Multiple Myeloma During Daratumumab-Based Therapy.

Hemophagocytic lymphohistiocytosis (HLH) is rare in patients with multiple myeloma (MM), and its significance during anti-CD38-based therapy remains unclear. We report the case of a 76-year-old man diagnosed with MM and treated with daratumumab, lenalidomide, and dexamethasone who developed HLH before an aggressive clinical relapse. Autopsy revealed diffuse extramedullary plasma cell infiltration, despite the minimal morphological evidence of hemophagocytosis. This case highlights the fact that HLH during immune-modifying therapy should be recognized as a critical clinical harbinger of rapid d…

В ходе химиотерапии был обнаружен продвинутый первичный рак трубчатой трубки в множестве миеломы: отчет о деле и литература.

Множественная миелома (ММ) является общей злокачественной опухолью кровеносной системы, с другой стороны, заболеваемость раком фаллопийских трубок невелика, и на ее долю приходится лишь один случай: 0.1%~1.8% гинекологических злокачественных опухолей. Это крайне редкое явление. two Болезни, которые происходят вместе. В этой газете мы приводим случай первичного рака фаллопийских труб, который был обнаружен и метастазирован в яичник во время химиотерапии для MM, и мы анализируем литературу. ПРЕЗИДЕНТ: Пациент был 69 возраст и постменопаузальный период 19 Годы. Она была доставлена в больницу из-з…

Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma.

BACKGROUND: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can induce deep responses in relapsed or refractory multiple myeloma, yet relapse remains frequent. Neither post-infusion maintenance nor salvage after CAR T-cell failure has an established standard. MAIN TEXT: This review synthesizes pivotal trials, real-world cohorts, and translational studies into a risk-adapted framework for longitudinal care. Relapse biology, target modulation, CAR T-cell persistence, immune reconstitution, measurable residual disease (MRD), and imaging are integrated to …

Refractory Protein-losing Enteropathy Complicated by Cytomegalovirus Enterocolitis after Chemotherapy for Multiple Myeloma: A Fatal Adult Case.

Protein-losing enteropathy (PLE) complicated by cytomegalovirus (CMV) enterocolitis is rare in adults. We report a fatal case of refractory PLE complicated by CMV enterocolitis after chemotherapy for multiple myeloma. A 71-year-old woman developed severe diarrhea and hypoalbuminemia after a single course of bortezomib-based therapy. CMV enterocolitis was diagnosed by an endoscopic biopsy despite initially negative blood CMV DNA. Although antiviral therapy controlled the CMV infection, PLE and intestinal ulceration persisted, leading to perforation and uncontrollable gastrointestinal bleeding. …

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients.

Multiple myeloma represents a systemic disease of the bone marrow (BM) niche, in which immune and skeletal pathways are tightly interconnected. However, the independent prognostic significance of bone and immune-related markers in newly diagnosed multiple myeloma (NDMM) remains incompletely understood. Semaphorin (Sema) 4D, activin-A, and periostin ELISA, LEGENDplex™ Human Bone Metabolism Panel and proteomic analysis for novel biomarker identification were conducted in 71 consecutive samples from NDMM patients. In 25 patients, genomic analysis was performed on sorted clonal plasma cells. NDMM …

Operative diagnosis of a meningioma-like intraosseous skull lesion revealing multiple myeloma: Case report and literature review.

BACKGROUND: Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal proliferation of clonal plasma cells. Skull involvement is common in MM, typically presenting as small "punched-out" lytic lesions; however, large destructive calvarial masses are uncommon and can radiologically mimic other skull tumors such as meningiomas, hemangiopericytomas, or metastatic disease, making tissue diagnosis essential. This report presents a case of MM initially misdiagnosed as an intraosseous meningioma, highlighting the diagnostic challenges of destructive calvarial lesions and the value o…

Gut Microbiome Composition Is Associated With Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients.

INTRODUCTION: Growing data support interactions between host-gut microbes and treatment responses in multiple myeloma (MM), where a higher abundance of Eubacterium hallii in stool samples has been found among MM patients with negative minimal residual disease after induction therapy. Here, we evaluated changes in the gut microbiome associated with daratumumab (dara) based therapy in 40 MM patients, before and after therapy. PATIENTS AND METHODS: Patients with relapsed MM and prior autologous transplantation who had received 1 to 4 prior lines of therapy were eligible. Two stool samples were c…

Clinical and immune features associated with chromosome 13q deletion and PRKCSH downregulation in newly diagnosed multiple myeloma.

BACKGROUND: Newly diagnosed multiple myeloma (NDMM) shows marked immune heterogeneity. Deletion of chromosome 13q [del(13q)] is common in multiple myeloma, yet its immunological significance remains unclear. METHODS: Peripheral blood immune profiles were evaluated in 132 NDMM patients using flow cytometry and a cytokine bead array. Publicly available transcriptomic cohorts were interrogated using differential gene expression testing, co-expression network analysis (WGCNA), and immune-cell deconvolution to derive del(13q)-related immune signatures, followed by survival analyses. RESULTS: Comp…

Diagnostic and potential prognostic associations of long noncoding RNAs LIFR-AS1 and SLCO4A1-AS1 in multiple myeloma.

There is growing evidence for the involvement of LncRNAs in the development of multiple myeloma (MM). We aimed to investigate the possible diagnostic and potential prognostic associations of two LncRNAs with oncogenic potential, LIFR-AS1 and SLCO4A1-AS1, in MM. Using qPCR, expression levels of both LncRNAs were quantified in 30 newly diagnosed patients with MM and 30 healthy controls. Their associations with clinicopathological parameters including serum protein electrophoresis, immunofixation, bone marrow, biochemical, hematological indices and the expression of IL-17 A and RORC, downstream a…

Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108.

BACKGROUND: Frailty and comorbidity substantially influence clinical outcomes in patients with multiple myeloma (MM), yet existing tools such as the IMWG frailty score and Charlson Comorbidity Index (CCI) have limitations in real-world applicability and disease specificity. OBJECTIVE: To develop and externally validate a multiple myeloma-specific comorbidity index (MM-CI) using real-world data from Korean and Japanese cohorts. MATERIALS AND METHODS: This retrospective study was conducted in two parts: (I) development of MM-CI using a nationwide Korean claims cohort of 17,273 MM patients diag…

Модели прогнозирования риска венозного тромбоэмболизма у пациентов с множественной миеломой: систематический обзор и метаанализ.

СОСТОЯНИЕ: Модели прогнозирования рисков помогают выявлять многих пациентов с миэломой (ММ), подверженных высокому риску венозного тромбоэмболизма (ВТЕ), и направлять клинические решения. Однако их применимость и точность остаются неясными. Цель этого исследования заключается в систематическом пересмотре существующих моделей риска VTE у пациентов с ОМ. Мы систематически искали PubMed, Embase, Cochrane Bibrary и Web of Science для изучения моделей прогнозирования рисков VTE у пациентов с MM до марта 31, 2026. Two Следователи независимо проверяли литературу, извлекали данные и оценивали риск пре

Совпадение в аннотации оригинала
BACKGROUND: Risk prediction models help identify multiple myeloma (MM) patients at high risk of venous thromboembolism (VTE) and guide clinical decisions. However, their applicability and accuracy remain unclear. This study aims to systematically review existing VTE risk models in MM patients. METHODS: We systematically searched PubMed, Embase, Cochrane Lib…